Previous 10 | Next 10 |
VANCOUVER, Washington, May 07, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, tod...
New data shows 525 mg dose achieves 95% response rate after the first 10 weeks of monotherapy with leronlimab Over 110 patients have reached almost one year of suppressed viral load with monotherapy on original dose of 350 mg or higher dosages Half-life of leronlimab is now con...
The following slide deck was published by CytoDyn Inc. in conjunction with this Read more ...
VANCOUVER, Washington, April 29, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), CytoDyn, a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that management will present a compa...
VANCOUVER, Washington, April 04, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company”) a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, to...
DENVER, Colo., April 2, 2019- (24/7MarketNews via COMTEX) Venture Market News for April 2, 2019. CytoDyn and Samsung BioLogics Enter into Agreement to Manufacture $1 Billion Worth of Leronlimab (PRO 140) to Meet Expected Demand for Future Revenues Post-Approval VANCOUVER, Washington, April...
CytoDyn ( OTCQB:CYDY ) has entered into an agreement with Samsung BioLogics for the clinical and commercial manufacturing of $1B worth of leronlimab (PRO 140). More news on: CytoDyn Inc., Healthcare stocks news, Read more ...
VANCOUVER, Washington, April 02, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company”) a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, to...
VANCOUVER, Washington, April 01, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company”) a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, hi...
Editor's note: Seeking Alpha is proud to welcome Theodore Zucconi as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more » NanoStri...
News, Short Squeeze, Breakout and More Instantly...
Terms of the settlement include $12,000,000 cash payment to CytoDyn and elimination of $14,000,000 accounts payable liability from the Company’s balance sheet VANCOUVER, Washington, July 09, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a bio...
VANCOUVER, Washington, June 27, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that its preclinical MASH study with SMC ...
VANCOUVER, Washington, May 28, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Dr. Jacob P. Lalezari, Chief Executiv...